…ACE inhibitor Prodrug hydrolysed to enalaprilat. Reduces mortality in heart failure with reduced ejection fraction — the effect is dose-dependent, and underdosing is more often…

…symptomatic patient with HFrEF who remains above 70 beats per minute despite maximally tolerated beta-blockade, where SHIFT demonstrated reduced risk of heart failure hospitalisation.

…no clinically significant negative inotropic effect and can therefore be used in heart failure with reduced ejection fraction when blood pressure or angina requires it…

…most β₁-selective of the routinely used beta-blockers, with documented mortality benefit in heart failure from CIBIS-II. Bioavailability is close to 90 % and…

…in heart failure (CHARM), and the first choice when an ACE inhibitor must be switched due to cough. The target dose in heart failure is…

…extends well beyond the diabetes indication. DAPA-HF demonstrated reduced cardiovascular death and worsening heart failure with reduced ejection fraction, DELIVER showed equivalent benefit with…

…and heart failure resembles that of selective COX-2 inhibitors and is seen already at doses below 100 mg/day and with short treatment duration…

…2 diabetes in EMPA-REG OUTCOME, reduced heart failure events regardless of ejection fraction in EMPEROR-Reduced and EMPEROR-Preserved, and slowed renal function decline…

…depression and generalised anxiety disorder. What governs dosing is not efficacy but the heart: a dose-dependent QT prolongation was identified, and the maximum dose…

…20–30 minutes after the infusion ends, it is useful in patients where beta-blockade is desirable but risky — impending heart failure, obstructive lung disease…

…vessels — completely without alpha effect. The result is that heart rate rises while systemic vascular resistance and diastolic blood pressure fall, so the drug raises…

Tambocor Class IC antiarrhythmic A potent sodium channel blocker with marked efficacy on atrial arrhythmias in structurally normal hearts. The CAST trial showed increased mortality…

…sätter först vid både depression och ångestsyndrom, och det bäst dokumenterade vid samtidig hjärt- och kärlsjukdom — svag CYP-hämning, ingen kliniskt relevant QT-förlängning i…

…fyra doser. Naproxen har den mest gynnsamma kardiovaskulära profilen bland NSAID och är därför förstahandsval när ett NSAID måste ges till patient med hjärt-kärlsjukdom.